Search Results - "Lublin, Fred D"

New multiple sclerosis phenotypic classification by Lublin, Fred D

“…In 1996, the clinical course of multiple sclerosis (MS) was characterized as relapsing-remitting, primary progressive, secondary progressive or progressive…”
Get more information

Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria by Thompson, Alan J, Banwell, Brenda L, Barkhof, Frederik, Carroll, William M, Coetzee, Timothy, Comi, Giancarlo, Correale, Jorge, Fazekas, Franz, Filippi, Massimo, Freedman, Mark S, Fujihara, Kazuo, Galetta, Steven L, Hartung, Hans Peter, Kappos, Ludwig, Lublin, Fred D, Marrie, Ruth Ann, Miller, Aaron E, Miller, David H, Montalban, Xavier, Mowry, Ellen M, Sorensen, Per Soelberg, Tintoré, Mar, Traboulsee, Anthony L, Trojano, Maria, Uitdehaag, Bernard M J, Vukusic, Sandra, Waubant, Emmanuelle, Weinshenker, Brian G, Reingold, Stephen C, Cohen, Jeffrey A

“…The 2010 McDonald criteria for the diagnosis of multiple sclerosis are widely used in research and clinical practice. Scientific advances in the past 7 years…”
Get full text

Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria by Polman, Chris H., Reingold, Stephen C., Banwell, Brenda, Clanet, Michel, Cohen, Jeffrey A., Filippi, Massimo, Fujihara, Kazuo, Havrdova, Eva, Hutchinson, Michael, Kappos, Ludwig, Lublin, Fred D., Montalban, Xavier, O'Connor, Paul, Sandberg-Wollheim, Magnhild, Thompson, Alan J., Waubant, Emmanuelle, Weinshenker, Brian, Wolinsky, Jerry S.

“…New evidence and consensus has led to further revision of the McDonald Criteria for diagnosis of multiple sclerosis. The use of imaging for demonstration of…”
Get full text

Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial by Calabresi, Peter A, Dr, Radue, Ernst-Wilhelm, Prof, Goodin, Douglas, MD, Jeffery, Douglas, MD, Rammohan, Kottil W, MD, Reder, Anthony T, MD, Vollmer, Timothy, MD, Agius, Mark A, MD, Kappos, Ludwig, Prof, Stites, Tracy, PhD, Li, Bingbing, PhD, Cappiello, Linda, MD, von Rosenstiel, Philipp, MD, Lublin, Fred D, MD

“…Summary Background Fingolimod has shown reductions in clinical and MRI disease activity in patients with relapsing-remitting multiple sclerosis. We further…”
Get full text

Randomized study combining interferon and glatiramer acetate in multiple sclerosis by Lublin, Fred D., Cofield, Stacey S., Cutter, Gary R., Conwit, Robin, Narayana, Ponnada A., Nelson, Flavia, Salter, Amber R., Gustafson, Tarah, Wolinsky, Jerry S.

“…Objective A double‐blind, randomized, controlled study was undertaken to determine whether combined use of interferon β‐1a (IFN) 30μg intramuscularly weekly…”
Get full text

Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study by Havrdova, Eva, MD, Galetta, Steven, MD, Hutchinson, Michael, MD, Stefoski, Dusan, MD, Bates, David, MD, Polman, Chris H, MD, O'Connor, Paul W, MD, Giovannoni, Gavin, PhD, Phillips, J Theodore, MD, Lublin, Fred D, MD, Pace, Amy, ScD, Kim, Richard, MD, Hyde, Robert, PhD

“…Summary Background The efficacy of natalizumab on clinical and radiological measures in the phase III Natalizumab Safety and Efficacy in Relapsing-Remitting…”
Get full text

A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis by Polman, Chris H, O'Connor, Paul W, Havrdova, Eva, Hutchinson, Michael, Kappos, Ludwig, Miller, David H, Phillips, J. Theodore, Lublin, Fred D, Giovannoni, Gavin, Wajgt, Andrzej, Toal, Martin, Lynn, Frances, Panzara, Michael A, Sandrock, Alfred W

“…This placebo-controlled, randomized trial of patients with relapsing multiple sclerosis demonstrated benefits of natalizumab (an α 4 integrin antagonist) in…”
Get full text

Detection of subtle gait disturbance and future fall risk in early multiple sclerosis by Brandstadter, Rachel, Ayeni, Oluwasheyi, Krieger, Stephen C., Harel, Noam Y., Escalon, Miguel X., Katz Sand, Ilana, Leavitt, Victoria M., Fabian, Michelle T., Buyukturkoglu, Korhan, Klineova, Sylvia, Riley, Claire S., Lublin, Fred D., Miller, Aaron E., Sumowski, James F.

“…OBJECTIVETo test the hypothesis that higher-challenge gait and balance tasks are more sensitive than traditional metrics to subtle patient-reported gait…”
Get full text

Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria" by Polman, Chris H., Reingold, Stephen C., Edan, Gilles, Filippi, Massimo, Hartung, Hans-Peter, Kappos, Ludwig, Lublin, Fred D., Metz, Luanne M., McFarland, Henry F., O'Connor, Paul W., Sandberg-Wollheim, Magnhild, Thompson, Alan J., Weinshenker, Brian G., Wolinsky, Jerry S.

“…New diagnostic criteria for multiple sclerosis integrating magnetic resonance image assessment with clinical and other paraclinical methods were introduced in…”
Get full text

Natalizumab plus Interferon Beta-1a for Relapsing Multiple Sclerosis by Rudick, Richard A, Stuart, William H, Calabresi, Peter A, Confavreux, Christian, Galetta, Steven L, Radue, Ernst-Wilhelm, Lublin, Fred D, Weinstock-Guttman, Bianca, Wynn, Daniel R, Lynn, Frances, Panzara, Michael A, Sandrock, Alfred W

“…In this randomized trial involving patients with relapsing multiple sclerosis who had had relapses despite treatment with interferon, natalizumab in…”
Get full text

Clinical Course of Multiple Sclerosis by Klineova, Sylvia, Lublin, Fred D

“…The 1996 originally established multiple sclerosis (MS) subtypes, based solely on clinical impression and consensus, were revised in 2013 to review potential…”
Get full text

Worsening MS—A reappraisal of how we characterize the MS disease course by Lublin, Fred D

Get full text

Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis by McDonald, W. Ian, Compston, Alistair, Edan, Gilles, Goodkin, Donald, Hartung, Hans-Peter, Lublin, Fred D., McFarland, Henry F., Paty, Donald W., Polman, Chris H., Reingold, Stephen C., Sandberg-Wollheim, Magnhild, Sibley, William, Thompson, Alan, Van Den Noort, Stanley, Weinshenker, Brian Y., Wolinsky, Jerry S.

“…The International Panel on MS Diagnosis presents revised diagnostic criteria for multiple sclerosis (MS). The focus remains on the objective demonstration of…”
Get full text

Disability Outcomes in the N-MOmentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum Disorder by Marignier, Romain, Bennett, Jeffrey L., Kim, Ho Jin, Weinshenker, Brian G., Pittock, Sean J., Wingerchuk, Dean, Fujihara, Kazuko, Paul, Friedemann, Cutter, Gary R., Green, Ari J., Aktas, Orhan, Hartung, Hans-Peter, Lublin, Fred D., Williams, Ian M., Drappa, Jorn, She, Dewei, Cimbora, Daniel, Rees, William, Smith, Michael, Ratchford, John N., Katz, Eliezer, Cree, Bruce A.C.

“…To assess treatment effects on Expanded Disability Status Scale (EDSS) score worsening and modified Rankin Scale (mRS) scores in the N-MOmentum trial of…”
Get full text

Polygenic liability for anxiety in association with comorbid anxiety in multiple sclerosis by Kowalec, Kaarina, Harder, Arvid, Dolovich, Casandra, Fitzgerald, Kathryn C., Salter, Amber, Lu, Yi, Bernstein, Charles N., Bolton, James M., Cutter, Gary, Fisk, John D., Gelernter, Joel, Graff, Lesley A., Hägg, Sara, Hitchon, Carol A., Levey, Daniel F., Lublin, Fred D., McKay, Kyla A., Patten, Scott, Patki, Amit, Stein, Murray B., Tiwari, Hemant K., Wolinsky, Jerry S., Marrie, Ruth A.

“…Objective Comorbid anxiety occurs often in MS and is associated with disability progression. Polygenic scores offer a possible means of anxiety risk prediction…”
Get full text

How patients with multiple sclerosis acquire disability by Lublin, Fred D, Häring, Dieter A, Ganjgahi, Habib, Ocampo, Alex, Hatami, Farhad, Čuklina, Jelena, Aarden, Piet, Dahlke, Frank, Arnold, Douglas L, Wiendl, Heinz, Chitnis, Tanuja, Nichols, Thomas E, Kieseier, Bernd C, Bermel, Robert A

“…Patients with multiple sclerosis acquire disability either through: (1) Relapse-associated worsening (RAW), or (2) progression independent of relapse activity…”
Get full text

Sleep disturbance and memory dysfunction in early multiple sclerosis by Sumowski, James F., Horng, Sam, Brandstadter, Rachel, Krieger, Stephen, Leavitt, Victoria M., Katz Sand, Ilana, Fabian, Michelle, Klineova, Sylvia, Graney, Robin, Riley, Claire S., Lublin, Fred D., Miller, Aaron E., Varga, Andrew W.

“…Objective Sleep‐dependent memory processing occurs in animals including humans, and disturbed sleep negatively affects memory. Sleep disturbance and memory…”
Get full text

Treatment of Multiple Sclerosis Exacerbations by Repovic, Pavle, MD, PhD, Lublin, Fred D., MD

“…The understanding of the mechanisms that lead to MS exacerbations continues to produce novel treatments for patients with relapsing forms of MS. However, even…”
Get full text

The 2013 clinical course descriptors for multiple sclerosis: A clarification by Lublin, Fred D., Coetzee, Timothy, Cohen, Jeffrey A., Marrie, Ruth A., Thompson, Alan J.

“…The clinical courses of multiple sclerosis were defined in 1996 and refined in 2013 to provide a time-based assessment of the current status of the individual…”
Get full text

Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial by Cree, Bruce A C, Bennett, Jeffrey L, Kim, Ho Jin, Weinshenker, Brian G, Pittock, Sean J, Wingerchuk, Dean M, Fujihara, Kazuo, Paul, Friedemann, Cutter, Gary R, Marignier, Romain, Green, Ari J, Aktas, Orhan, Hartung, Hans-Peter, Lublin, Fred D, Drappa, Jorn, Barron, Gerard, Madani, Soraya, Ratchford, John N, She, Dewei, Cimbora, Daniel, Katz, Eliezer

“…No approved therapies exist for neuromyelitis optica spectrum disorder (NMOSD), a rare, relapsing, autoimmune, inflammatory disease of the CNS that causes…”
Get full text